Analysts
OMV is covered by 22 financial analysts, who provide their own research analyses and earnings estimates on OMV. Analysts may occasionally suspend their coverage whenever the institution they are affiliated with is involved in carrying out a financial transaction for OMV. On this page we provide you with the list of the contact details and recommendations of the institutions regularly publishing research reports on OMV that have consented with our disclosing of this information.
Furthermore, Vara Research collects on behalf of OMV earnings estimates from the equity analysts currently covering the company.
| Company | Analyst | Contact | Recommendation | TP | Last estimate |
|---|---|---|---|---|---|
| AlphaValue | Isabelle Zhang | Add | 49.30 | Apr. 30, 2024 | |
| Bank Pekao | Krzysztof KozieĊ | Hold | 43.00 | Dec. 11, 2023 | |
| Barclays | Ramchandra Kamath | Underweight | 50.00 | Oct. 3, 2023 | |
| Berenberg |
Henry Tarr |
Hold | 49.00 | May 16, 2024 | |
| Bernstein | Irene Himona | R.S. | R.S. | Mar. 21, 2024 | |
| Concorde Securities | Mihaly Gajda | Buy | 48.10 | Mar. 19, 2024 | |
| Erste Group Bank | Tamas Pletser | Buy | 52.50 | Mar. 28, 2024 | |
| Exane BNP Paribas | Paul Redman | Underperform | 38.00 | June 12, 2024 | |
| Goldman Sachs |
Michele Della Vigna |
– | – | – | |
| Jefferies |
Giacomo Romeo |
Buy | 44.00 | June 28, 2024 | |
| J.P. Morgan | Matthew Lofting | Neutral | 44.00 |
June 13, 2024 |
|
| Kepler Cheuvreux | Bertrand Hodée | Buy | 49.00 | June 17, 2024 | |
| LBBW | Achim Wittmann | Buy | 50.00 | May 3, 2024 | |
| Morgan Stanley | Sasikanth Chilukuru | Equalweight | 46.10 | May 14, 2024 | |
| PKO BP | Adam Milewicz | Hold |
47.30 |
May 13, 2024 | |
| Raiffeisen Bank International | Oleg Galbur | Buy | 55.00 | Jan. 16, 2024 | |
| Redburn | Peter Low | Neutral | 44.00 | Jan. 16, 2024 | |
| Santander | Tomasz Krukowski | Neutral | 47.00 | May 29, 2024 | |
| Trigon | Michal Kozak | Buy | 47.30 | July 22, 2024 | |
| UBS | Joshua Stone | Neutral | 43.00 | July 2, 2024 | |
| Wood & Company | Jonathan Lamb | Buy | 56.40 | Mar. 5, 2024 |
Note: Due to legal reasons the disclosure of individual target prices and recommendations is not possible for all the financial analysts currently covering OMV.
Ahead of each quarterly earnings announcement, Vara Research collects the earnings estimates on behalf of OMV from the equity analysts covering the company. These numbers serve as a respective proxy for the market’s expectation of OMV’s quarterly earnings results. For the second quarter of 2024, 20 analysts have contributed with their estimates.
The consensus numbers for the Operating Result and net income attributable to stockholders are at clean CCS (Current Cost of Supply; inventory holding gains and losses). That means that they do not include any special items or CCS effects.
Q2 2024:
| In EUR mn | Median | Min | Max |
|---|---|---|---|
|
Clean CCS Operating Result |
1,287 | 1,003 | 1,488 |
|
Clean Operating Result Chemicals & Materials |
135 | 68 | 196 |
|
Clean CCS Operating Result Fuels & Feedstock |
271 | 215 | 385 |
| Clean Operating Result Energy | 892 | 678 | 1,017 |
|
Clean CCS net income attributable to stockholders of the parent |
541 | 387 | 607 |
| Cash flow from operating activities excluding net working capital effects | 1,183 | 859 | 2,000 |
| Cash flow from operating activities | 1,178 | 678 | 2,050 |
As of July 24, 2024, 12.00 pm CEST
Vara Research collects on behalf of OMV full year earnings estimates for the upcoming three years from the equity analysts currently covering the company. These numbers become a proxy for what the market expects in terms of OMV’s results. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments. OMV did not participate in the compilation of the estimates and it does not endorse them.
The consensus numbers for the Operating Result and net income attributable to stockholders are at clean CCS (Current Cost of Supply; inventory holding gains and losses). That means that they do not include any special items or CCS effects.
Disclaimer:
This document has been issued by OMV Aktiengesellschaft (“the Company”) for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The Company does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. The Company gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Reference to assessments serves only for reader information and is non-binding. This document does not imply that the Company subscribes to these opinions or conclusions in any form whatsoever, or that the Company supports or confirms them. The Company accepts no liability for the selection, current relevance, completeness or correctness of the analysts’ assessments reproduced here. None of the information provided is to be understood as an offer for purchase of OMV securities, or to be advertising same. Any liability on the part the Company for losses incurred by third parties arising from the information contained on this Internet site is precluded.